Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bron

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Bone Marrow Transplantation|January 1, 1991
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients)A Hagenbeek, T Philip, D Bron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphomaR Somers, P Carde, J Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study GroupU Tirelli, D Errante, M Van Glabbeke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative GroupJ H Meerwaldt, P Carde, R Somers, et al.
Haematologica|July 16, 1999
The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factorM F Dresse, M Boogaerts, C Vermylen, et al.
Journal of the National Cancer Institute|January 4, 2001
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC studyH C Kluin-Nelemans, V Zagonel, A Anastasopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignanciesM Moreau, J Klastersky, A Schwarzbold, et al.
Bone Marrow Transplantation|November 9, 2004
Stem cell transplantation from identical twins in patients with myelodysplastic syndromesN Kröger, R Brand, A van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trialC Guglielmi, F Gomez, T Philip, et al.
Blood|December 15, 1995
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of responseM Cazzola, D Messinger, V Battistel, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Bone Marrow Transplantation|January 1, 1991
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients)A Hagenbeek, T Philip, D Bron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphomaR Somers, P Carde, J Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study GroupU Tirelli, D Errante, M Van Glabbeke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative GroupJ H Meerwaldt, P Carde, R Somers, et al.
Haematologica|July 16, 1999
The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factorM F Dresse, M Boogaerts, C Vermylen, et al.
Journal of the National Cancer Institute|January 4, 2001
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC studyH C Kluin-Nelemans, V Zagonel, A Anastasopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignanciesM Moreau, J Klastersky, A Schwarzbold, et al.
Bone Marrow Transplantation|November 9, 2004
Stem cell transplantation from identical twins in patients with myelodysplastic syndromesN Kröger, R Brand, A van Biezen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trialC Guglielmi, F Gomez, T Philip, et al.
Blood|December 15, 1995
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of responseM Cazzola, D Messinger, V Battistel, et al.
Pageof 14